TABLE 1.
Demographic and hospitalization-related characteristics in statin users and nonusers
| Characteristic | Value(s) by treatment groupa |
|||
|---|---|---|---|---|
| Unexposed (n = 16,448) | Pretreated without continuation (n = 344) | Pretreated with continuation (n = 159) | De novo (n = 187) | |
| Age (yr) | 67.0 ± 12.5 | 69.7 ± 10.9* | 71.7 ± 10.5* | 71.6 ± 11.3* |
| Body mass index | 26.6 ± 7.1 | 28.3 ± 7.1* | 27.3 ± 6.8 | 27.3 ± 6.5 |
| Demographics [no. (%)] | ||||
| Male gender | 16,068 (97.7) | 341 (99.1) | 157 (98.7) | 183 (97.9) |
| White race | 10,202 (62.0) | 250* (72.7) | 105 (66.0) | 112 (59.9) |
| Hispanic ethnicity | 1,013 (6.2) | 18 (5.2) | 7 (4.4) | 9 (4.8) |
| Yr [no. (%)] | ||||
| 2002–2005 | 6,605 (40.2) | 121 (35.2) | 54 (34.0) | 48* (25.7) |
| 2006–2009 | 5,621 (34.2) | 133 (38.7) | 59 (37.1) | 72* (38.5) |
| 2010–2013 | 4,222 (25.7) | 90 (26.2) | 46 (28.9) | 67* (35.8) |
| Admission source [no. (%)] | ||||
| Home | 14,632 (89.0) | 303* (88.1) | 145* (91.2) | 161 (86.1) |
| Hospital | 669 (4.1) | 24* (7.0) | 10* (6.3) | 14 (7.5) |
| Nursing home | 1,147 (7.0) | 17* (4.9) | 4* (2.5) | 12 (6.4) |
| Intensive care at culture | 3,262 (19.8) | 78 (22.7) | 47* (29.6) | 49* (26.2) |
| Treating specialty [no. (%)] | ||||
| General medicine | 9,807 (59.6) | 185 (53.8) | 82* (51.6) | 106* (56.7) |
| Intensive care | 3,468 (21.1) | 85 (24.7) | 50* (31.5) | 56* (29.9) |
| Surgery | 1,749 (10.6) | 47 (13.7) | 22* (13.8) | 17* (9.1) |
| Other | 1,424 (8.7) | 27 (7.8) | 5* (3.1) | 8* (4.3) |
| Region of facility [no. (%)] | ||||
| Midwest | 3,096 (18.8) | 58 (16.9) | 30* (18.9) | 39* (20.9) |
| Northeast | 2,295 (13.9) | 50 (14.5) | 14* (8.8) | 32* (17.1) |
| South | 7,372 (44.8) | 151 (43.9) | 99* (62.3) | 94* (50.3) |
| West | 3,685 (22.4) | 85 (24.7) | 16* (10.1) | 22* (11.8) |
| Source of infectionb [no. (%)] | ||||
| Catheter | 349 (2.1) | 10 (2.9) | 3 (1.9) | 2 (1.1) |
| Endocarditisc | 579 (3.5) | 8 (2.3) | 2 (1.3) | 13 (6.9) |
| Respiratory culture site | 1,216 (7.4) | 27 (7.8) | 9 (5.7) | 7 (3.7) |
| Skin and soft tissue culture site | 2,130 (12.9) | 55 (16.0) | 14 (8.8) | 25 (13.4) |
| Urine | 2,083 (12.7) | 31* (9.0) | 7* (4.4) | 31 (16.6) |
| S. aureus pathogen [no. (%)] | ||||
| MRSA infection | 8,184 (49.8) | 172 (50) | 73 (45.9) | 78* (41.7) |
| MSSA infection | 8,264 (50.2) | 172 (50.0) | 86 (54.1) | 109* (58.3) |
| Sepsis [no. (%)] | 13,676 (83.2) | 269* (78.2) | 115* (72.3) | 156 (83.4) |
a
Data are means ± standard deviations or number (percent) of patients. An asterisk indicates a P value of <0.05 for pairwise comparison between the statin exposure group and nonuser group.
b
Culture-confirmed source of infection ±24 h from culture collection unless indicated otherwise.
c
Source of infection identified from ICD-9-CM diagnosis codes ±24 h from culture collection.